Related Experiment Video

Updated: Jul 4, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Home-based infusion therapy for patients with Fabry disease

A Cousins1, P Lee, D Rorman

  • 1Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, London, UK.

British Journal of Nursing (Mark Allen Publishing)
|June 20, 2008
PubMed

Insights

Home infusion therapy for Fabry disease using agalsidase beta offers a safe and practical alternative to hospital treatments. This patient-centered approach improves quality of life and optimizes hospital resources.

Area of Science:

  • Biochemistry
  • Genetics
  • Pharmacology

Background:

  • Fabry disease is a progressive, life-threatening inherited disorder requiring lifelong enzyme replacement therapy.
  • Hospital-based agalsidase therapy is often perceived as inconvenient by patients and healthcare providers.
  • Home-based infusion therapy presents a patient-preferred alternative for managing Fabry disease.

Purpose of the Study:

  • To review clinical experiences with agalsidase beta home infusion therapy.
  • To outline the organization of safe, patient-centered homecare for Fabry disease.
  • To assess the feasibility and impact of home infusion therapy.

Main Methods:

  • Review of collective clinical experiences with agalsidase beta home infusion.
  • Identification of prerequisites for safe home therapy (stable patient, suitable environment).
  • Discussion of nurse-assisted and self-care infusion models.

Main Results:

  • Home infusion therapy is safe and practical, significantly improving patient quality of life.
  • Home therapy reduces constraints on hospital resources.
  • Eligible patients can benefit from home infusion therapy without delay.

Conclusions:

  • Home-based agalsidase beta infusion therapy is a viable and beneficial treatment for Fabry disease.
  • Patient-centered homecare models enhance treatment convenience and adherence.
  • The principles of home infusion therapy can be applied to other enzyme replacement therapies.

Related Concept Videos

Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this measurement...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...